← Evidence map

ArticleGland surgery2025

Comparison of pathological complete response (pCR) between short-term (<6 cycles) and long-term (≥6 cycles) neoadjuvant trastuzumab therapy for HER2-positive breast cancer: a systematic review and meta-analysis of randomized controlled trials.

Siyi Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Comparison of pathological complete response (pCR) between short-term (<6 cycles) and long-term (≥6 cycles) neoadjuvant trastuzumab therapy for HER2-positive breast cancer: a systematic review and meta-analysis of randomized controlled trials. | Socratic